Page 18 - Lupin

Lupin willing to take partners to bring mRNA Covid-19 vaccines to India

Executive says company is looking for tie-ups to bring in drugs like Remdesivir

Lupin Q4 net profit up 18% at Rs 460 cr; FY21 profit at Rs 1,216 cr

Drug maker Lupin on Thursday reported an 18 per cent increase in its consolidated net profit at Rs 460 crore for the fourth quarter, driven by robust sales across domestic and international markets

Lupin soars 8%, hits over three-year high on heavy volumes

The stock surpassed its previous high of Rs 1,121.85 touched on September 2020 and was trading at the highest level since July 2017

Stocks to watch: Nestle India, Hero Moto, ICICI Securities, Cyient, Lupin

Cyient, Tata Elxsi and 10 other companies will release their quarterly earnings on April 22

Titan, Lupin: How to trade dark horses in Rakesh Jhunjhunwala's portfolio

Titan Company needs to decisively cross and sustain above Rs 1,500 levels, supported by volume, to attract the interest of market participants

Lupin plans expansion, aims to enter Chinese market in the next one year

The company has now decided to focus on specialty drugs. The annual price cuts made the Japanese generics market unattractive

Regulatory clearances, US growth near term triggers for Lupin

India business has seen steady uptick growth over the last few quarters

F&O Expiry: Sensex sinks 536 pts; broader mkts outperform; bank stocks up

In the broader market, the S&P BSE MidCap index ended 0.4 per cen lower while the smallcap counterpart closed down 0.45 per cent.

Lupin, Reliance Industries: Stock picks by Ajit Mishra of Religare Broking

We're seeing consistent buying interest in the pharma pack and Lupin is also catching up with the other pharma majors

New product launches to drive growth for Lupin, US business a key trigger

This should reverse the US underperformance in FY15-20 with margins too moving up sharply

Select pharma shares rally; Suven Pharma up 13%, Laurus nears record high

Healthcare companies to post decent growth in revenues in Q3FY21

Pharma, healthcare growing, but they face challenges beyond Covid-19

These sectors will face another tough year after coronavirus pandemic, the first challenge being vaccination of India's 1.3 billion people. Devangshu Datta explains the opportunities and threats

Nifty Pharma index hits new record high; Laurus Labs, Glenmark Pharma up 3%

Cipla, Cadila Healthcare, Lupin, Sun Pharma and Aurobindo Pharma from the Nifty Pharma index were up in the range of 1 per cent to 2 per cent on the NSE

Nifty is trading in highly overbought zone, avoid fresh long: Sameet Chavan

13,650 is the immediate support which, if breached, could result in some profit booking and drag the index towards 13,500-13,470

Lupin rises on settling dispute with Gavis and Novel; gains 5% in four days

On Wednesday, Lupin announced in a BSE filing that its dispute with the sellers in the Gavis and Novel transaction has been resolved amicably to the satisfaction of all parties.

November domestic pharma sales grow just 1% after strong show last month

Oct growth rate was 9.6%; Most big corporates saw volumes drop in November

Divi's Lab, Aurobindo Pharma: Are pharma stocks losing their sheen? Read on

Till Nifty Pharma holds above the 11,180 mark, the bullish bias will prevail, charts suggest.

USFDA issues 13 observations after inspection of Lupin arm's facility in US

Drug firm Lupin said the US health regulator has issued 13 observations after inspection of its subsidiary's Somerset facility in New Jersey

Lupin: Q2 unimpressive, more triggers required to drive stock

US growth has picked up as anticipated, but India and a few other markets still lag

With US sales recovering, Lupin Q2 profit up 97% over Q1 to Rs 211 cr

The revenues, however, dropped by 1.2 percent on a year on year (YoY) basis to Rs 3,835 crore, but sequentially the revenues rose 8.7 percent